Bryan Oronsky

Company: EpicentRx

Job title: Chief Medical Officer

Seminars:

Navigating Clinical & Post-Approval Considerations for Inflammasome Inhibitors with Diverse Uses and Future Implications 9:30 am

Gain insights into the advanced stage of development for novel inflammasome inhibitors Examine the broader implications of inflammasome inhibitor approvals, including offlabel usage considerations, insurance coverage challenges, and their impact on existing treatment paradigm Explore how the approval and widespread adoption of inflammasome inhibitors may disrupt traditional therapeutic approaches, particularly in comparison to corticosteroidsRead more

day: Day 2